GABA_A receptors as targets for novel anxiolytic drugs

References

• Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, Sur C, Melillo D, Bristow L, Bromidge F, Ragan I, Kerby J, Street L, Carling R, Castro JL, Whiting P, Dawson GR, McKernan RM. TPA023 [7,(1,1-dimthylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)3-(2-fuorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2-and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 2006; 316: 410–422
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 2004; 8: 1–10
   Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. evidence-based guidelines for the pharmacological treatment of anxiety disordrs: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567–596
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Burrows GD, DuPont RL, Jr, Lesser IM, Noyes R, Jr, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45: 413–422
   PubMedGoogle Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J. Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic disorders. World J Biol Psychiatry 2002; 3: 171–199
   PubMedGoogle Scholar
• Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABAA receptor. Nat Neurosci 2005; 6: 565–575
   Google Scholar
• Carling RW, Madin A, Guiblin A, Russell MG, Moore KW, Mitchinson A, Sohal B, Pike A, Cool SM, Ragan IC, McKernan RM, Quirk K, Ferris P, Marshall G, Thompson SA, Wafford KA, Dawson GR, Atack JR, Harrison T, Castro JL, Street LJ. 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine: a functionally selective gamma.aminobutyric acid (A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. J Med Chem 2005; 48: 7089–7092
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Schecter JM, Tyrka AR, Mello MF, Haggarty R, Price LH. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 2006; 67: 66–71
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumaic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 2006; 184: 21–25
   PubMed Web of Science ®Google Scholar
• Crestani F, Lorez M, Baer K, Essrich C, Benke D, Laurent JP, Belzung C, Fritschy JM, Luscher B, Mohler H. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat Neurosci 1999; 9: 833–839
   Google Scholar
• Crestani F, Low K, Keist R, Mandelli M, Mohler H, Rudolph U. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol 2001; 59: 422–445
   Google Scholar
• Crestani F, Keist R, Fritschy JM, Benke D, Vogt K, Prut L, Bluthmann H, Mohler H, Rudolph U. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci USA 2002; 99: 8980–8985
   PubMed Web of Science ®Google Scholar
• Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792–1798
   PubMed Web of Science ®Google Scholar
• Dawson GR, Collinson N, Atack JR. Development of subtype selective GABAA modulators. CNS Spectrums 2005; 10: 21–27
   PubMedGoogle Scholar
• Dias R, Sheppard WF, Fradley RL, Garrett EM, Stanley JL, Tye SJ, Goodacre S, Lincoln RJ, Cool SM, Conley R, Hallett D, Humphries AC, Thompson SA, Wafford KA, Street LJ, Castro JL, Whiting PJ, Rosahl TW, Atack JR, McKernan RM, Dawson GR, Reynolds DS. Evidence for a significant role of alpha-3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 2005; 25: 10682–10688
   PubMed Web of Science ®Google Scholar
• Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314: 180–181
   PubMed Web of Science ®Google Scholar
• Faulhaber J, Steiger A, Lancel M. The GABAA agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans. Psychopharmcology 1997; 130: 285–291
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–249
   PubMed Web of Science ®Google Scholar
• Goodacre SC, Street LJ, Hallett DJ, Crawforth JM, Kelly S, Owens AP, Blackaby WP, Lewis RT, Stanley J, Smith AJ, Ferris P, Sohal B, Cook SM, Pike A, Brown N, Wafford KA, Marshall G, Castro JL, Atack JR. Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders. J Med Chem 2006; 49: 35–38
   PubMed Web of Science ®Google Scholar
• Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Francon D, Avenet P, Schoemeker H, Evanno Y, Sevrin M, Geroge P, Scatton B. SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev 2003; 9: 3–20
   PubMedGoogle Scholar
• Gulinello M, Gong QH, Smith SS. Progesterone withdrawal increases the anxiolytic actions of gaboxadol: role of alpha4betadelta GABA(A) receptors. Neuroreport 2003; 14: 43–46
   PubMedGoogle Scholar
• Hoehn-Saric R. Effects of THIP on chronic anxiety. Psychophopharmacology 1983; 80: 338–341
   PubMedGoogle Scholar
• Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the national comorbidity survey replication. Arch Gen Psychiatry 2006; 63: 415–424
   PubMed Web of Science ®Google Scholar
• Kita A, Kohayakawa H, Kinoshita T, Ochi Y, Nakamichi K, Kurumiya S, Furukawa K, Oka M. Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br J Pharmacol 2004; 142: 1059–1072
   PubMed Web of Science ®Google Scholar
• Lancel M, Faulhaber J. The GABAA agonist THIP (gaboxadol) increases non-REM sleep and enhances delta activity in the rat. Neuroreport 1996; 7: 2241–2245
   PubMed Web of Science ®Google Scholar
• Langen B, Egerland U, Bernoster K, Dost R, Unverferth K, Rundfeldt C. Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor. J Pharmacol Exp Ther 2005; 314: 717–724
   PubMedGoogle Scholar
• Lippa A, Czobor P, Stark J, Beer B, Kostakis E, Gravielle M, Bandyopadhyay S, Russek SJ, Gibbs TT, Farb DH, Skolnick P. Selective anxiolysis produced by ocinaplon, a GABAA receptor modulator. Proc Natl Acad Sci USA 2005; 102: 7380–7385
   PubMed Web of Science ®Google Scholar
• Löw K, Crestani F, Keist R, Benke D, Brünig I, Benson JA, Fritschy J-M, Rülicke T, Bluethmann H, Möhler H, Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000; 290: 131–134
   PubMed Web of Science ®Google Scholar
• McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Gerrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ. Nat Neurosci 2000; 3: 587–592
   PubMed Web of Science ®Google Scholar
• Möhler H, Crestani F, Rudolph U. GABAA-receptor subtypes: a new pharmacology. Curr Opin Pharmacol 2001; 1: 22–25
   PubMedGoogle Scholar
• Möhler H, Fritschy J-M, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002; 300: 2–8
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Malizia AL. New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001; 179: 390–396
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol 2002; 5: 315–325
   PubMed Web of Science ®Google Scholar
• Pande AC, Feltner DE, Jefferson JW, Davidson JRT, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder. J Clin Psychopharmacol 2004; 24: 141–149
   PubMed Web of Science ®Google Scholar
• Papadopoulos V, Lecanu L, Brown RC, Han Z, Yao ZX. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 2005; 138: 749–756
   PubMedGoogle Scholar
• Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992; 6: 2311–2322
   PubMed Web of Science ®Google Scholar
• Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder. J Clin Psychopharmacol 2005; 25: 151–158
   PubMed Web of Science ®Google Scholar
• Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 2005; 66: 1401–1408
   PubMed Web of Science ®Google Scholar
• Puia G, Santi MR, Vicini S, Pritchett DB, Purdy RH, Paul SM, Seeburg PH, Costa E. Neurosteroids act on recombinant human GABAA receptors. Neuron 1990; 4: 759–765
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022–1030
   PubMed Web of Science ®Google Scholar
• Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64: 1245–1249
   PubMed Web of Science ®Google Scholar
• Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy J-M, Martin JR, Bluethmann H, Möhler H. Benzodiazepine actions mediated by specific (γ-aminobutyric acidA receptor subtypes. Nature 1999; 401: 796–797
   PubMed Web of Science ®Google Scholar
• Rudolph U, Crestani F, Möhler H. GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 2001; 22: 188–194
   PubMed Web of Science ®Google Scholar
• Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003; 28: 139–168
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999; 22: 410–416
   PubMed Web of Science ®Google Scholar
• Russell MG, Carling RW, Street LJ, Hallet DJ, Goodacre S, Mezzogori E, Reader M, Cook SM, Bromidge FA, Newman R, Smith AJ, Wafford KA, Marshall GR, Reynolds DS, Dias R, Ferris P, Stanley J, Lincoln R, Tye SJ, Sheppard WF, Sohal B, Pike A, Dominguez M, Attack JR, Castro JL. Discovery of imidazo(1,2-b)(1,2,4)triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety. J Med Chem 2006; 49: 1235–1238
   PubMed Web of Science ®Google Scholar
• Schmitt U, Hiemke C. Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav Pharmacol 1999; 10: 131–137
   PubMed Web of Science ®Google Scholar
• Selak I. Pregabalin (Pfizer). Curr Opin Invest Drugs 2001; 2: 828–834
   PubMedGoogle Scholar
• Sherif F, Harro J, El-Hwuegi A, Oreland L. Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory activity. Pharmacol Biochem Behav 1994; 49: 801–805
   PubMedGoogle Scholar
• Strohle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 2003; 60: 161–168
   PubMed Web of Science ®Google Scholar
• Tauber M, Calame-Droz E, Prut L, Rudolph U, Crestani F. Alpha2-gamma-aminobutyric acaid (GABA)A receptors are the molecular substrates mediating precipitation of narcosis but not of sedation by the combined use of diazepam and alcohol in vivo. Eur J Neurosci 2003; 18: 2599–2604
   PubMedGoogle Scholar
• van Rijnsoever C, Tauber M, Choulli MK, Keist R, Rudolph U, Mohler H, Fritschy JM, Crestani F. Requirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice. J Neurosci 2004; 24: 6785–6790
   PubMed Web of Science ®Google Scholar
• Whiting PJ. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery?. Drug Discov Today 2003; 8: 445–450
   PubMed Web of Science ®Google Scholar
• Wieland HA, Lüddens H, Seeburg PH. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem 1992; 267: 1426–1429
   PubMed Web of Science ®Google Scholar
• Yee BK, Hauser J, Dolgov VV, Keist R, Mohler H, Rudolph U, Feldon J. GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extnction of conditioned fear. Eur J Neurosci 2004; 20: 1928–1936
   PubMedGoogle Scholar
• Zwanzger P, Baghai T, Boerner RJ, Möller H-J, Rupprecht R. Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 2001a; 21: 539–540
   PubMedGoogle Scholar
• Zwanzger P, Baghai TC, Schüle C, Minov C, Padberg F, Möller H-J, Rupprecht R. Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 2001b; 62: 656–657
   PubMed Web of Science ®Google Scholar
• Zwanzger P, Baghai TC, Schüle C, Ströhle A, Padberg F, Kathmann N, Schwarz M, Möller H-J, Rupprecht R. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 2001c; 25: 699–703
   PubMed Web of Science ®Google Scholar
• Zwanzger P, Eser D, Padberg F, Baghai TC, Schüle C, Rotzer F, Ella R, Möller H-J, Rupprecht R. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety 2003; 18: 140–143
   PubMedGoogle Scholar